Trial Profile

PHASE II NEOADJUVANT STUDY of PD-1 INHIBITOR DOSTARLIMAB (TSR-042) VS. COMBINATION of TIM-3 INHIBITOR COBOLIMAB (TSR-022) and PD-1 INHIBITOR DOSTARLIMAB (TSR-042) in RESECTABLE STAGE III or OLIGOMETASTATIC STAGE IV MELANOMA (NEO-MEL-T)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Nov 2024 Planned number of patients changed from 56 to 62.
17 Jun 2024 Planned End Date changed from 1 Oct 2027 to 15 Apr 2029.
17 Jun 2024 Planned primary completion date changed from 1 Jan 2025 to 15 Sep 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com